Webinar Banner

Webinar RegistrationThe Therapeutic Pipeline for Age-Related Macular Degeneration and Diabetic Macular Edema: Where Do We Stand and Where Are We Headed?

Dec 9, 2022, 2:00 PM in Universal Time UTC

facebook
twitter
linkedin
email

Anti-vascular endothelial growth factor (anti-VEGF) antibodies have been the pillar of therapy for patients with neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) for nearly two decades. Unfortunately, anti-VEGF therapy requires frequent, repeated intravitreal injections that pose significant burdens for patients, their caregivers, and the healthcare system. Additionally, anti-VEGF therapy is completely ineffective for patient with atrophic age-related macular degeneration. Angiopoietin (Ang) pathways have recently shown the potential to provide a new treatment target that can reduce inflammation in neovascular AMD and DME. Likewise, the cleavage of complement protein C5 is being targeted for treatment options in geographic atrophy. In this session, we will focus on current and emerging therapies for AMD and DME. Lecturer: Dr. Arghavan Almony, Carolina Eye Associates, North Carolina, USA

Webinar Logo

Topic

The Therapeutic Pipeline for Age-Related Macular Degeneration and Diabetic Macular Edema: Where Do We Stand and Where Are We Headed?

Description

Anti-vascular endothelial growth factor (anti-VEGF) antibodies have been the pillar of therapy for patients with neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) for nearly two decades. Unfortunately, anti-VEGF therapy requires frequent, repeated intravitreal injections that pose significant burdens for patients, their caregivers, and the healthcare system. Additionally, anti-VEGF therapy is completely ineffective for patient with atrophic age-related macular degeneration. Angiopoietin (Ang) pathways have recently shown the potential to provide a new treatment target that can reduce inflammation in neovascular AMD and DME. Likewise, the cleavage of complement protein C5 is being targeted for treatment options in geographic atrophy. In this session, we will focus on current and emerging therapies for AMD and DME. Lecturer: Dr. Arghavan Almony, Carolina Eye Associates, North Carolina, USA

Time

Dec 9, 2022, 2:00 PM in Universal Time UTC

Webinar Logo

Webinar Registration

* Required information